Mary Hesdorffer, NP and Executive Director of the Mesothelioma Applied Research Foundation, discusses the latest advances in treatment options for mesothelioma. Results from early-stage clinical trials show a future of promising treatments, including the MORAb-009 antibody that targets mesothelin and the CBP501 compound. This interview was filmed at the “Malignant Mesothelioma: Knowledge Is Hope“ Conference on September 28, 2012. Read more about Mary Hesdorffer. View presentation slides for the conference.